- Home
- Companies
- Hookipa Pharma Inc.
- Products
- Replicating Technology
Replicating Technology
Our proprietary replicating technology was designed to provide the beneficial properties of our non-replicating technology but to induce an even more robust immune response. Unlike naturally occurring arenaviruses which have two genomic segments, our replicating constructs were engineered to have three segments in order to allow for the introduction of genomic space in which to insert additional target antigens of choice. As a result of the larger genome the virus’ ability to replicate is reduced (attenuated).
Advantages of replicating technology
Based on preclinical data, our replicating technology offers the same advantages as our non-replicating technology, with the following additional benefits:
Quantitatively - Even More Robust CD8+ T Cell Response
Our replicating technology is designed to induce a T cell response that directs more than 50% of a body’s T cells to focus on a single target of choice. This response is approximately ten times greater than the response induced by our non-replicating technology. We believe our technology results in an immunotherapeutic approach with potential for greater potency than existing therapeutic treatments.
Qualitatively - Immunological Memory and Protection Against Challenge
Our replicating technology has shown the ability to trigger a long term T cell response. Furthermore, in various animal models replicating therapy resulted in protection against a cancer re-challenge months after primary treatment and response to replicating.